- Home
- EDF vs THRD Comparison
EDF vs THRD Comparison
Compare EDF & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- THRD
- Stock Information
- Founded
- EDF 2010
- THRD 2019
- Country
- EDF United States
- THRD United States
- Employees
- EDF N/A
- THRD N/A
- Industry
- EDF Investment Managers
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- THRD Health Care
- Exchange
- EDF Nasdaq
- THRD Nasdaq
- Market Cap
- EDF 148.8M
- THRD 164.2M
- IPO Year
- EDF N/A
- THRD 2022
- Fundamental
- Price
- EDF $4.93
- THRD $5.15
- Analyst Decision
- EDF
- THRD Hold
- Analyst Count
- EDF 0
- THRD 3
- Target Price
- EDF N/A
- THRD $5.00
- AVG Volume (30 Days)
- EDF 160.6K
- THRD 1.1M
- Earning Date
- EDF 01-01-0001
- THRD 05-08-2025
- Dividend Yield
- EDF 13.14%
- THRD N/A
- EPS Growth
- EDF N/A
- THRD N/A
- EPS
- EDF N/A
- THRD N/A
- Revenue
- EDF N/A
- THRD N/A
- Revenue This Year
- EDF N/A
- THRD N/A
- Revenue Next Year
- EDF N/A
- THRD N/A
- P/E Ratio
- EDF N/A
- THRD N/A
- Revenue Growth
- EDF N/A
- THRD N/A
- 52 Week Low
- EDF $3.51
- THRD $3.18
- 52 Week High
- EDF $5.50
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- EDF 52.63
- THRD 76.76
- Support Level
- EDF $4.81
- THRD $5.11
- Resistance Level
- EDF $4.92
- THRD $5.25
- Average True Range (ATR)
- EDF 0.10
- THRD 0.05
- MACD
- EDF 0.02
- THRD -0.04
- Stochastic Oscillator
- EDF 64.63
- THRD 27.54
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.